Wellnex Life (ASX:WNX) : Appendix 4C and Quarterly Report for June 2024 Quarter

We are pleased to share Wellnex Life (ASX:WNX), owner and developer of some of Australia's leading health brands, has recently published a key ASX announcement. 

Announcement Highlights

• Record Cash inflows from brand sales
  
• Operating profit of $0.5 million (Q4 FY24)
  
• Quarterly Cash Receipts (Q4 FY24) $4.9 million
• 56% rise from previous quarter (Q3 FY24: $3.12 million)
• 122% rise in margins for 6 months ending June 30 compared to previous 6 months
• Investment of $1.35 million in the quarter for the purchase 12 month's supply of ingredients and packaging for Pain Away and for the launch of new Wakey Wakey product lines
• Extension of new 2 innovative lines of Wakey Wakey which have commenced ranging in major pharmacy and grocery retailers in July
• Launch of medicinal cannabis brand commenced sales in July for the SAS-B market
• Wellnex Life progresses with dual listing on the London Stock Exchange
• Placement completed with participation from UK based investors post close of quarter

Wellnex Life (ASX: WNX) is pleased to provide the following operational update along with its Appendix 4C for the quarter ended June 2024. ("Q4 FY24").

The company recorded Cash Receipts for Q4 FY24 of $4.9 million, an increase of 56% on the previous quarter (Q3 FY24: $3.12 million), with 82% of all cash receipts coming from brand sales resulting in an operating profit of $0.5 million for the quarter.

The increasing sales of Wellnex Life's brands has resulted in margins increasing 120% in the last half of FY24 compared to the first half of FY24 to 40% (H1FY24: 18%).

Read the full Wellnex Life announcement here.

To learn more about Wellnex Life and stay up to date with investor information, subscribe to the Company's Chairman’s List.